APLM Stock Summary and Trading Ideas (Apollomics - Class A | NASDAQ:APLM)

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Apollomics - Class A trades on the NASDAQ stock market under the symbol APLM.

As of December 31, 2025, APLM stock price climbed to $21.87 with 25,278 million shares trading.

APLM has a beta of 1.34, meaning it tends to be more sensitive to market movements. APLM has a correlation of 0.02 to the broad based SPY ETF.

APLM has a market cap of $46.88 million. This is considered a Sub-Micro Cap stock.

APLM has outperformed the market in the last year with a price return of +115.9% while the SPY ETF gained +17.6%. APLM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +18.6% and +28.5%, respectively, while the SPY returned +3.0% and +1.1%, respectively.

APLM support price is $18.60 and resistance is $22.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLM shares will trade within this expected range on the day.